Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, uncoated - excipient ingredients: magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; purified talc; microcrystalline cellulose - leah is indicated for use as: - an oral contraceptive. - treatment of moderate acne vulgaris in women who seek oral contraception - treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of leah for pmdd was not assessed beyond 3 cycles. leah has not been evaluated for treatment of pms (premenstrual syndrome), see clinical trials.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 0.03 mg; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: hypromellose; magnesium stearate; purified talc; lactose monohydrate; titanium dioxide; microcrystalline cellulose - for use as an oral contraceptive.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - cyproterone acetate,ethinylestradiol -

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - drospirenone, quantity: 3 mg; ethinylestradiol, quantity: 20 microgram - tablet, film coated - excipient ingredients: lactose; magnesium stearate; povidone; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - this medicine is indicated for use as: ? an oral contraceptive. ? treatment of moderate acne vulgaris in women who seek oral contraception. ? treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of drospirenone 3 mg /ethinylestradiol 20 ?g for pmdd was not assessed beyond 3 cycles. drospirenone 3 mg /ethinylestradiol 20 ?g has not been evaluated for treatment of pms (premenstrual syndrome), see section 5.1 pharmacodynamic properties - clinical trials.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - drospirenone,ethinylestradiol -

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ethinylestradiol, quantity: 30 microgram; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: lactose; povidone; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - indicated for use as an oral contraceptive

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - drospirenone,ethinylestradiol -

Malta - angleščina - Medicines Authority

mithra pharmaceuticals s.a rue saint-georges 5, 4000, liege, belgium - ethinylestradiol, drospirenone - film-coated tablet - ethinylestradiol 0.02 mg drospirenone 3 mg - sex hormones and modulators of the genital system

Malta - angleščina - Medicines Authority

mithra pharmaceuticals s.a rue saint-georges 5, 4000, liege, belgium - ethinylestradiol, drospirenone - film-coated tablet - ethinylestradiol 0.02 mg drospirenone 3 mg - sex hormones and modulators of the genital system

Malta - angleščina - Medicines Authority

mithra pharmaceuticals s.a rue saint-georges 5, 4000, liege, belgium - ethinylestradiol, drospirenone - film-coated tablet - ethinylestradiol 0.2 mg drospirenone 3 mg - sex hormones and modulators of the genital system